BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26718269)

  • 1. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
    Liu L; Xiang J; Chen R; Fu D; Hong D; Hao J; Li Y; Li J; Li S; Mou Y; Mai G; Ni Q; Peng L; Qin R; Qian H; Shao C; Sun B; Sun Y; Tao M; Tian B; Wang H; Wang J; Wang L; Wang W; Wang W; Zhang J; Zhao G; Zhou J; Yu X;
    Int J Oncol; 2016 Mar; 48(3):900-7. PubMed ID: 26718269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden.
    Liu L; Xu HX; Wang WQ; Wu CT; Xiang JF; Liu C; Long J; Xu J; Fu de L; Ni QX; Houchen CW; Postier RG; Li M; Yu XJ
    Oncotarget; 2016 Feb; 7(5):5943-56. PubMed ID: 26745601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125.
    Liang C; Shi S; Meng Q; Liang D; Hua J; Qin Y; Zhang B; Xu J; Ni Q; Yu X
    Int J Cancer; 2018 Dec; 143(11):2919-2931. PubMed ID: 29978477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.
    Das S; Rachagani S; Torres-Gonzalez MP; Lakshmanan I; Majhi PD; Smith LM; Wagner KU; Batra SK
    Oncotarget; 2015 Mar; 6(8):5772-87. PubMed ID: 25691062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathobiological implications of MUC16 expression in pancreatic cancer.
    Haridas D; Chakraborty S; Ponnusamy MP; Lakshmanan I; Rachagani S; Cruz E; Kumar S; Das S; Lele SM; Anderson JM; Wittel UA; Hollingsworth MA; Batra SK
    PLoS One; 2011; 6(10):e26839. PubMed ID: 22066010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
    Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
    Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
    Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
    Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.
    Szymańska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
    Talanta; 2020 Jan; 206():120187. PubMed ID: 31514860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
    Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
    Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
    Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
    Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
    Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
    Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
    J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases.
    Coppin L; Benomar K; Corfiotti F; Cattan S; Renaud F; Lapere C; Leteurtre E; Vantyghem MC; Truant S; Pigny P
    Pancreatology; 2016; 16(1):115-20. PubMed ID: 26613889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system.
    Yang C; Cheng H; Luo G; Lu Y; Guo M; Jin K; Wang Z; Yu X; Liu C
    Eur J Surg Oncol; 2017 Nov; 43(11):2112-2118. PubMed ID: 28802662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
    Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
    Sci Rep; 2013; 3():1870. PubMed ID: 23694968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.
    Jiang K; Tan E; Sayegh Z; Centeno B; Malafa M; Coppola D
    Appl Immunohistochem Mol Morphol; 2017 Oct; 25(9):620-623. PubMed ID: 27093451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type.
    Higashi M; Yamada N; Yokoyama S; Kitamoto S; Tabata K; Koriyama C; Batra SK; Yonezawa S
    Pathobiology; 2012; 79(2):101-6. PubMed ID: 22286058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
    White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
    Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.
    Tyler C; Kapur A; Felder M; Belisle JA; Trautman C; Gubbels JA; Connor JP; Patankar MS
    Am J Reprod Immunol; 2012 Jul; 68(1):28-37. PubMed ID: 22380506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells.
    Lei Y; Zang R; Lu Z; Zhang G; Huang J; Liu C; Wang Z; Mao S; Che Y; Wang X; Zheng S; Fang L; Sun N; He J
    Cell Death Dis; 2020 Oct; 11(10):853. PubMed ID: 33056994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.